In this study, the G allele of the rs2306283 variant of the SLCO1B1 gene was associated with an almost three-fold increase in the risk of developing severe central nervous system toxicity during the consolidation phase of ALL treatment. The gene discussed is SLCO1B1; the disease is acute lymphoblastic leukemia.